Condition

Benign Prostatic Hyperplasia

ClinicalTrials.gov condition label

Clinical trials34

Recruiting6

Common interventions25

Lead sponsors shown15

Clinical trials

34 shown

MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base MorphologyNCT07694752 · 2026-07-15

RECRUITING

Spinal Versus General Anesthesia in Open Simple ProstatectomyNCT07643415 · 2026-04-29

RECRUITING

Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate CancerNCT07526675 · 2026-04-10

RECRUITING

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.NCT05148156 · 2026-02-11

RECRUITING

Sacral Neuromodulation for Male Overactive Bladder (MOAB)NCT06511141 · 2024-10-22

RECRUITING

Customized TULSA-PRO Ablation RegistryNCT05001477 · 2021-10-27

RECRUITING

Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling ElderlyNCT07357714 · 2026-01-01

NOT_YET_RECRUITING

Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)NCT07510685 · 2025-02-01

COMPLETED

The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis AnalysisNCT06589154 · 2024-10-10

COMPLETED

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTsNCT06051942 · 2022-11-22

ACTIVE_NOT_RECRUITING

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery EmbolizationNCT04879940 · 2022-02-23

ACTIVE_NOT_RECRUITING

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and PainNCT05803096 · 2021-12-12

COMPLETED

Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the BladderNCT05077852 · 2021-12-12

UNKNOWN

Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.NCT04853914 · 2021-09-13

COMPLETED

Anti-Androgen Treatment for COVID-19NCT04446429 · 2020-10-21

COMPLETED

An Observational Study of Radial Access Embolization Procedures Using HydroPearl MicrospheresNCT04272216 · 2020-02-06

COMPLETED

Learning Curve of Digital Rectal Examination for Prostate Cancer Among InternshipNCT03479359 · 2018-02-26

UNKNOWN

MRI Guided Transurethral HIFU for Various Prostate DiseasesNCT03350529 · 2017-07-24

COMPLETED

Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the ProstateNCT02822963 · 2016-03-01

WITHDRAWN

Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral ProstatectomyNCT03912766 · 2016-02-01

COMPLETED

Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem CellsNCT02425800 · 2015-07-28

COMPLETED

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)NCT02167919 · 2014-07-01

COMPLETED

Application of DWI in Diagnosis of Prostate CancerNCT04962269 · 2013-06-12

COMPLETED

2013 Annual National Digital Rectal Exam (DRE) Day StudyNCT01886547 · 2013-06-01

COMPLETED

Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) LevelsNCT01678313 · 2012-08-01

COMPLETED

Choline Metabolites in People With Prostate Cancer and Those With Benign HyperplasiaNCT06380062 · 2012-01-12

COMPLETED

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)NCT01520441 · 2011-03-01

WITHDRAWN

3D Recording of a Trans-rectal Prostate BiopsyNCT01314456 · 2011-03-01

UNKNOWN

Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy OutcomeNCT01826617 · 2010-12-01

COMPLETED

Korean Practice Patterns for Screening PCA(Prostate Cancer)NCT01371513 · 2010-05-01

COMPLETED

Economic Analyses of the REDUCE TrialNCT01337258 · 2010-01-01

COMPLETED

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate CarcinomaNCT00400894 · 2005-09-01

UNKNOWN

Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerNCT00375765 · 2005-04-01

COMPLETED

Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)NCT01250483 · 2001-01-01

COMPLETED

Common interventions

DutasterideDRUG2Axonics SNM SystemDEVICE1BioblationPROCEDURE1BOTOXDRUG1Closed-System Bladder Irrigation Flow Switch DeviceDEVICE1continuous screeningOTHER1Cytology Specimen Collection ProcedureOTHER1Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)DRUG1Doxazosin 4 mg every day (QD)DRUG1General anesthesiaPROCEDURE1HIFU treatmentDEVICE1Laboratory Biomarker AnalysisOTHER1Merit Medical EmbospheresDEVICE1MicrospheresDEVICE1MRIDIAGNOSTIC_TEST1MRI guided transurethral HIFU ablation of prostatic tissueDEVICE1Multi-modal artificial intelligence model (BEAM)DIAGNOSTIC_TEST1NaviGoDEVICE1OxygenOTHER1PlaceboDRUG1Plasma concentration of cholineOTHER1Prostate health screeningOTHER1ProxalutamideDRUG1PSA measurement, uroflowmetry, IPSS, transrectal ultrasonographyOTHER1Radiation TherapyRADIATION1

Leading sponsors

GlaxoSmithKline3St. Luke's Medical Center, Philippines2Ankara Training and Research Hospital1Applied Biology, Inc.1Axonics, Inc.1Benha University1Beth Israel Deaconess Medical Center1Buddhist Tzu Chi General Hospital1Changhai Hospital1Chinese PLA General Hospital1EDAP TMS S.A.1H. Lee Moffitt Cancer Center and Research Institute1HaEmek Medical Center, Israel1Hitit University1Jiangsu Taizhou People's Hospital1

Trial status mix

COMPLETED19

RECRUITING6

UNKNOWN4

ACTIVE_NOT_RECRUITING2

WITHDRAWN2

NOT_YET_RECRUITING1

Phase mix

NA11

PHASE22

PHASE42

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.